Movement Disorders

Expert clinicians offer their insight on costs of Alzheimer drug development, a new agent for generalized myasthenia gravis, migraine in the emergency department, educational sleep medicine “boot camps”, AES 2021, and more.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 14, 2022.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

The results of a phase 4 study demonstrate the efficacy of APOKYN® (apomorphine hydrochloride injection) treatment.

Although both are dopamine reuptake inhibitors, those on MAO-B inhibitors demonstrated greater mean PDQ-39 mobility scores and EuroQol 5-dimension 3-level scores over a median of 4.5 years.

Here's what is coming soon to NeurologyLive®.

Neurology News Network for the week ending January 8, 2022. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 7, 2022.

Patients treated with valbenazine demonstrated favorable outcomes on all secondary outcomes over placebo, as well showed no new safety signals.

Six months post-surgery, patients on either general anesthesia or local anesthesia demonstrated similar motor improvements, indicated by scores on the MDS-UPDRS, as well as similar safety findings.

The latest CME course features a trio of experts that will help advanced practice providers provide optimal patient management and education in DBS treatment.

The safety profile in the low-dose cohort (6 x 1012 vg) is supportive of continued enrollment for a higher-dose cohort of 6 x 1013 vg. Additional data are anticipated to be announced in the second quarter of 2022.

Here's what is coming soon to NeurologyLive®.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 31, 2021.

Take a look back at some of the most-viewed, top video series with key experts in neurology and their in-depth discussions, part of NeurologyLive®'s Year in Review.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jennifer Majersik, MD, MS.

As part of NeurologyLive®'s Year in Review, take a look at some of the most engaging conversations the team has had with experts in neurology this past year.

As part of NeurologyLive®'s Year in Review, take a look at some of the most listened to and engaging conversations from the Mind Moments™ podcast from this past year.

These news stories were the top conversations in the field and were often included in NeurologyLive®'s coverage in movement disorders such as Parkinson disease, Huntington disease, and essential tremor, among others.

As part of NeurologyLive®'s Year in Review, take a look at some of the biggest FDA approvals and decisions from this past year.

As part of NeurologyLive®'s Year in Review, take a look at some of the best features that have been published on the site this year.

Here's what is coming soon to NeurologyLive®.

Take a look back at some of the most top video interviews with key experts in neurology and their insights and perspectives on topics in neurology subspecialties, as part of NeurologyLive®'s Year in Review.

Although combination carbidopa-levodopa has become a standard for the treatment of many of the motor features of PD to this day, gait dysfunction remains a difficult symptom to treat.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 24, 2021.